Next Article in Journal
Comparison of [18F]PSMA-1007 with [68Ga]Ga-PSMA-11 PET/CT in Restaging of Prostate Cancer Patients with PSA Relapse
Previous Article in Journal
Chick Chorioallantoic Membrane (CAM) Assays as a Model of Patient-Derived Xenografts from Circulating Cancer Stem Cells (cCSCs) in Breast Cancer Patients
Previous Article in Special Issue
Rintatolimod (Ampligen®) Enhances Numbers of Peripheral B Cells and Is Associated with Longer Survival in Patients with Locally Advanced and Metastasized Pancreatic Cancer Pre-Treated with FOLFIRINOX: A Single-Center Named Patient Program
 
 
Review
Peer-Review Record

Orchestrating Treatment Modalities in Metastatic Pancreatic Neuroendocrine Tumors—Need for a Conductor

Cancers 2022, 14(6), 1478; https://doi.org/10.3390/cancers14061478
by Alexander R. Siebenhüner 1,2,*, Melanie Langheinrich 3, Juliane Friemel 4, Niklaus Schäfer 5, Dilmurodjon Eshmuminov 6 and Kuno Lehmann 2,6
Reviewer 1:
Reviewer 2: Anonymous
Cancers 2022, 14(6), 1478; https://doi.org/10.3390/cancers14061478
Submission received: 30 January 2022 / Revised: 28 February 2022 / Accepted: 10 March 2022 / Published: 14 March 2022
(This article belongs to the Special Issue Combination and Innovative Therapies for Pancreatic Cancer)

Round 1

Reviewer 1 Report

This is a comprehensive review of the management of metastatic pancreas neuroendocrine tumors.  There were a few grammatical and spelling errors which need revision.

I caution the authors on the language used when describing the role for liver transplantation in metastatic pancreas NET.  Contrastingly, there is inadequate discussion for the role of interventional radiology with locoregional liver therapies (e.g. TACE, y90, etc).

The musical references ("allegro") are appreciated by this reviewer, but I suspect many readers may find them distracting and potentially confusing.  

Finally, I believe a more formal meta-analysis would be more appropriate than this review.  

Author Response

Response to Reviewer 1 Comments

 

Point 1

This is a comprehensive review of the management of metastatic pancreas neuroendocrine tumors.  There were a few grammatical and spelling errors which need revision.

Response 1: We thank reviewer 1 for his evaluation and judgement of our review. We worked on the grammar and English within the revised version. However, we think to use the MDPI English editing service for a perfect presentation of our review if this is still needed.

Point 2

I caution the authors on the language used when describing the role for liver transplantation in metastatic pancreas NET.  Contrastingly, there is inadequate discussion for the role of interventional radiology with locoregional liver therapies (e.g. TACE, y90, etc).

Response 2: We thank reviewer 1 for his valuable statement in sight of liver transplantation. We have modified this passage. In addition we highlighted the role of interventional radiology and local therapies to liver metastasis.

Point 3

The musical references ("allegro") are appreciated by this reviewer, but I suspect many readers may find them distracting and potentially confusing.  

Response 3: We thank the reviewer 1 for adressing this point. We thought it would revitalize the paper if we combine the subheadings with some musicical references. However, we do not want to confuse the reader and have added the meaning in brackets now.

Point 4

Finally, I believe a more formal meta-analysis would be more appropriate than this review.  

 

Response 4: Bringing and analysing our points to a meta-analysis would be an approbiate step. However, as this was not a systematic review, no formal inclusion/exclusion criteria were selected. We cited studies that provided information regarding evaluation of surgery under systemic treatment as PRRT or MKIs or ICIs, focusing on downstaging and enabling surgery in this sequence in pNET. Thus, with focus on evaluation for surgery in different aspects in the sequence of pNET we thought that several studies would have been excluded from this narrative review although with their impact in a special focus (e.g. downstaging the tumor by PRRT) they are at that stage an important source to consider. In the end we did not change our setting to a meta-analysis and we are concinced that the current statement of our paper is still of high interest and valuable to evaluate surgery in pNET within different settings in advanced stages.

 

Reviewer 2 Report

Pancreatic neuroendocrine tumors are not recognized before the advanced stages when the tumor is hormonally active or the patient has symptoms related to extensive metastasis. In the review paper, the authors highlighted the time point for surgery for pancreatic neuroendocrine tumors. The topic is timely. The manuscript is well written. The text is clear and easy to read. I would still suggest a minor grammar and English language check before publication.

Author Response

Point 1

Pancreatic neuroendocrine tumors are not recognized before the advanced stages when the tumor is hormonally active or the patient has symptoms related to extensive metastasis. In the review paper, the authors highlighted the time point for surgery for pancreatic neuroendocrine tumors. The topic is timely. The manuscript is well written. The text is clear and easy to read. I would still suggest a minor grammar and English language check before publication.

 

Response 1: We thank reviewer 2 for his evaluation and judgement of our review. We worked on the grammar and English within the revised version. However, we think to use the MDPI English editing service for a perfect presentation of our review if this is still needed.

Author Response File: Author Response.docx

Round 2

Reviewer 1 Report

Appreciate the revisions.  

Back to TopTop